Salanersen

N/A

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NameSalanersen
Drug Alias NameBIIB-115ION-306
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionSurvival motor neuron protein stimulants
TargetsSurvival motor neuron protein
Therapy Area/IndicationsMuscular Atrophy, Spinal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Idec Research LtdIonis Pharmaceuticals IncBiogen Inc +[4] 
Inactive CompaniesN/A
Active IndicationsMuscular Atrophy, Spinal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A